DFV890 for Knee Osteoarthritis
Trial Summary
Will I have to stop taking my current medications?
The trial requires stopping certain medications before participating. You must not have had local treatments like viscosupplementation or corticosteroids in the knee within 12 weeks before starting, and you need to stop certain pain medications and immunomodulatory drugs within a specific time frame before screening.
What is the purpose of this trial?
This trial is testing a new medication called DFV890 to see if it can help people with painful knee osteoarthritis. The study will check if the medication can reduce knee pain and improve how well the knee works. Participants will be monitored for safety and how well they tolerate the medication.
Eligibility Criteria
Adults aged 50-80 with knee osteoarthritis, pain in the target knee for most days over the past 3 months, and certain levels of inflammation as shown by blood tests and MRI. They must weigh at least 50 kg with a BMI of 18-35 kg/m2. Excluded are those with other arthritis types, severe malalignment in their knee, certain blood disorders or infections, or using prohibited medications.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive DFV890 or placebo to assess efficacy, safety, and tolerability in reducing knee pain
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- DFV890
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD